NCT05517226View on ClinicalTrials.gov

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

PHASE1TerminatedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions

Hepatic Impairment

Interventions

COMBINATION_PRODUCT

Cotadutide

Participants will receive cotadutide subcutaneously.

Trial Locations (3)

33014

Research Site, Hialeah

78215

Research Site, San Antonio

78229

Research Site, San Antonio

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY